Crinetics Pharmaceuticals, Inc. (CRNX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $39.31 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03

• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $41.42, a 24.61% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $33.24, a 72.14% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $19.31, a 11.14% decline year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $21.73, a 36.67% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $33.27, a 22.90% increase from fiscal 2024.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $27.07, a 31.66% increase from fiscal 2023.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $20.56, a 6.64% increase from fiscal 2022.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $19.28, a 0.21% increase from fiscal 2021.